-       Report 
- October 2022
-  194 Pages 
- Global 
   From       €4449EUR$5,000USD£3,917GBP 
          -       Report 
- January 2024
-  213 Pages 
- Global 
   From       €4138EUR$4,650USD£3,642GBP 
          -       Report 
- September 2022
-  110 Pages 
- Global 
   From       €4894EUR$5,500USD£4,308GBP 
          -       Report 
- August 2021
-  77 Pages 
- Global 
   From       €4405EUR$4,950USD£3,877GBP 
          -       Report 
- September 2025
-  150 Pages 
- India 
   From       €3515EUR$3,950USD£3,094GBP 
           -       Report 
- December 2022
-  77 Pages 
- Global 
   From       €4405EUR$4,950USD£3,877GBP 
          -       Report 
- April 2021
-  377 Pages 
- Global 
   From       €3555EUR$3,995USD£3,129GBP 
          From       €1780EUR$2,000USD£1,567GBP 
          -       Report 
- November 2022
-  125 Pages 
- Global 
   From       €2216EUR$2,490USD£1,950GBP 
          -       Report 
- January 2023
-  343 Pages 
- Global 
   From       €4449EUR$5,000USD£3,917GBP 
          -       Report 
- March 2024
-  200 Pages 
- Global 
   From       €3693EUR$4,150USD£3,251GBP 
          -       Report 
- January 2024
-  200 Pages 
- Global 
   From       €3693EUR$4,150USD£3,251GBP 
            -       Report 
- July 2024
-  100 Pages 
- Global 
   From       €2670EUR$3,000USD£2,350GBP 
      €3337EUR$3,750USD£2,937GBP 
            -       Report 
- July 2024
-  100 Pages 
- Global 
   From       €2670EUR$3,000USD£2,350GBP 
      €3337EUR$3,750USD£2,937GBP 
            -       Report 
- April 2024
-  30 Pages 
- Global 
   From       €2314EUR$2,600USD£2,037GBP 
      €2892EUR$3,250USD£2,546GBP 
          -       Report 
- July 2024
-  120 Pages 
- Global 
   From       €4227EUR$4,750USD£3,721GBP 
          -       Report 
- April 2023
-  120 Pages 
- Global 
   From       €4227EUR$4,750USD£3,721GBP 
          -       Report 
- August 2025
-  82 Pages 
- India 
   From       €3115EUR$3,500USD£2,742GBP 
          -       Report 
- October 2023
-  128 Pages 
- North America 
   From       €3559EUR$4,000USD£3,133GBP 
          -       Report 
- August 2023
-  114 Pages 
- Global 
   From       €4004EUR$4,500USD£3,525GBP 
       
      The RNA Vaccine market is a subset of the larger Vaccine market, which is composed of products designed to prevent and treat infectious diseases. RNA Vaccines are a relatively new type of vaccine, which use genetic material to stimulate an immune response. This type of vaccine is particularly attractive due to its potential to be quickly developed and manufactured, as well as its ability to target a wide range of diseases.
RNA Vaccines are being developed for a variety of diseases, including    influenza, malaria, and cancer. These vaccines are being studied in clinical trials, and some have already been approved for use in humans.
The RNA Vaccine market is expected to grow in the coming years, as more vaccines are developed and approved. This growth is driven by the increasing demand for vaccines, as well as the potential for RNA Vaccines to be used to treat a wide range of diseases.
Some companies in the RNA Vaccine market include Moderna, Inovio Pharmaceuticals, CureVac, and Arcturus Therapeutics. Show Less   Read more